Navigation Links
Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing
Date:10/28/2008

VANCOUVER, Oct. 28 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) (the "Company") today announced that it has completed an initial closing of the financing announced on October 14, 2008 and amended on October 17, 2008, raising gross proceeds of $4.66 million. The closing involved a brokered and non-brokered private placement of 31,084,435 units at a price of $0.15 for each unit. Each unit consisted of one common share and one-half of one common share purchase warrant. Each full warrant is exercisable for one common share at a price of $0.20 per share. The warrants may be exercised for a period of 36 months from the closing date. Subject to delivery of necessary funds and documents, a further non-brokered financing of approximately $340,000 is expected to close within the next few days on the same terms, bringing the gross proceeds raised by that time to $5.0 million.

The common shares issued under the initial closing will have a hold period under Canadian law until March 1, 2009. The hold period for the additional common shares issued in the subsequent closing, if any, will be four months from the date of the closing.

Net proceeds of this offering will be used for working capital purposes, in particular toward the launch of the Flu A+B test sold by 3M Medical and the cardiovascular test line to be marketed by Roche Diagnostics.

"This financing, coupled with the commitments of our partners puts us in a much stronger position to take advantage of opportunities in the diagnostic market, as our partners prepare to market our two key product candidates, Flu A+B Test, which 3M has commenced selling this month, and NT-proBNP Test expected to be launched by Roche Diagnostics in the first quarter of 2009," said S. Wayne Kay, CEO. "We are also continuing to explore new opportunities with potential partners interested in funding further development applications in clinical areas not covered by our current partnersh
'/>"/>

SOURCE Response Biomedical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 BambooFlooringChina.com ... the company has proudly released its new collection of ... discounted rates, up to 29% off. , According ... and sturdy tree-like grass, making it a highly renewable resource. ... products have a mixing color which comes from natural bamboo ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... 2014 Discount-Dress.com is an important ... firm is to increase the company’s online market share by ... selection of bridesmaid dresses and announced a bridesmaid dress promotion ... until Dec. 30, 2014. All the dresses from this company ... , In fact, Discount-Dress.com is very good at manufacturing wedding ...
(Date:11/22/2014)... Nocturia is defined by the ... the individual has to wake at night one ... – Pipeline Review, H2 2014” provides comprehensive information ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
Breaking Medicine News(10 mins):Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
... Karen Ignagni, President and CEO of America,s Health Insurance ... the President,s budget:"Today,s budget submission sends a signal to ... prioritizing health care. We applaud the President for ... resources to put our nation on a path towards ...
... SEO Online PR & Marketing Consultancy, is pleased to announce the ... successful Industry Directory, offering free listings to relevant specialist industries. ... ... B2B, SEO Online PR & Marketing Consultancy , is pleased ...
... N.C., Feb. 26 Arbor Pharmaceuticals, a specialty,pharmaceutical ... the company has launched XYLAREX - a first-in-class ... media (middle ear,infections). XYLAREX is a novel ... the number of ear infections children experience. ...
... Feb. 26 A lawsuit was filed today by ... who contracted salmonella poisoning,after eating at a Blueberry Hill ... child was hospitalized for three days as a result ... Cook County Department of Health,after the Communicable Disease Unit ...
... groups nationwide to receive National Autism Conference DVD ... Association (NAA) today announced its receipt of a ... (CWF) to disseminate DVD sets of complete presentations ... organizations throughout the United States, U.S. territories, and ...
... to continuing multi-pronged effort to raise awarenessWASHINGTON, Feb. 26 ... for a Drug-Free America offers some promising news regarding ... According to the 20th annual Partnership Attitude Tracking Survey ... about drugs and alcohol, an increased number of teens ...
Cached Medicine News:Health News:AHIP Statement on the President's Budget 2Health News:Simply Marcomms Launch New Specialist Online Industry Directories 2Health News:Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children 2Health News:National Autism Association Announces American Legion Child Welfare Grant for Autism Outreach 2Health News:New Partnership for a Drug-Free America 20th Annual Study Shows Progress in Teens Recognizing Dangers of OTC Cough Medicine Abuse 2Health News:New Partnership for a Drug-Free America 20th Annual Study Shows Progress in Teens Recognizing Dangers of OTC Cough Medicine Abuse 3
(Date:11/21/2014)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) is proud ... Vision, Innovation, and Leadership has been awarded to Stuart ... an individual who has had a significant impact on the ... several decades. "I am honored to receive the ... Ph.D., CEO of PTC Therapeutics, Inc. "When I founded PTC ...
(Date:11/21/2014)...  Edwards Lifesciences Corporation (NYSE: EW ), ... and hemodynamic monitoring, announced today that it will increase ... strong launch of Edwards Lifesciences Foundation,s new charitable initiative, ... global communities where its employees live and work. ... exceed $8 million, including more than $7 million in ...
(Date:11/21/2014)... Telbec/ - KLOX Technologies Inc. ("KLOX" or the "Company") ... Todd Martensen has been hired to ... Chief Commercial Officer, to oversee KLOX,s commercial launch of ... the treatment of chronic and other hard-to-heal wounds, as ... Europe . Mr. Martensen, a seasoned ...
Breaking Medicine Technology:PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4
... , , ROCKVILLE, Md. , ... ) announced today that the company has decided to discontinue ... ROVI Pharmaceuticals ( Madrid : ROVI) to develop Novavax,s virus-like-particle ... .  This decision is due to the companies, inability to ...
... , SALT LAKE CITY , Feb. ... Corporation ("WorldHeart" or "Company"), a developer of mechanical circulatory systems, ... Company  received a NASDAQ Staff Deficiency Letter indicating that the ... Rule requires the Company to have at least three independent ...
Cached Medicine Technology:Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 2Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 4NASDAQ Stock Market Confirms WorldHeart's Compliance With NASDAQ Listing Rule 5605 2
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... primary known naturally-occurring stimulant of red blood ... human EPO is 18.2 kDa. Due to ... an estimated molecular mass of ~30.5 kDa. ... unique structure, the EPO receptor bears some ...
... Alpha Fetoprotein (AFP) is a 68 kDa protein, ... the fetal liver and yolk sac [1]. ... weeks gestation, and production rates reach 19-26 g/min ... and estimates of total fetal AFP continue to ...
Medicine Products: